{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:32:16Z","timestamp":1789705936348,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007771","name":"\u015al\u0105ski Uniwersytet Medyczny","doi-asserted-by":"publisher","award":["KNW-1-037\/K\/9\/O"],"award-info":[{"award-number":["KNW-1-037\/K\/9\/O"]}],"id":[{"id":"10.13039\/100007771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007771","name":"\u015al\u0105ski Uniwersytet Medyczny","doi-asserted-by":"publisher","award":["KNW-1-055\/K\/9\/O"],"award-info":[{"award-number":["KNW-1-055\/K\/9\/O"]}],"id":[{"id":"10.13039\/100007771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007771","name":"Medical University of Silesia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007771","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A large body of research has focused on fluoroquinolones. It was shown that this class of synthetic antibiotics could possess antiviral activity as a broad range of anti-infective activities. Based on these findings, we have undertaken in silico molecular docking study to demonstrate, for the first time, the principle for the potential evidence pointing ciprofloxacin and moxifloxacin ability to interact with COVID-19 Main Protease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In silico molecular docking and molecular dynamics techniques were applied to assess the potential for ciprofloxacin and moxifloxacin interaction with COVID-19 Main Protease (M\n                      <jats:sup>pro<\/jats:sup>\n                      ). Chloroquine and nelfinavir were used as positive controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We revealed that the tested antibiotics exert strong capacity for binding to COVID-19 Main Protease (M\n                      <jats:sup>pro<\/jats:sup>\n                      ). According to the results obtained from the GOLD docking program, ciprofloxacin and moxifloxacin bind to the protein active site more strongly than the native ligand. When comparing with positive controls, a detailed analysis of the ligand\u2013protein interactions shows that the tested fluoroquinolones exert a greater number of protein interactions than chloroquine and nelfinavir. Moreover, lower binding energy values obtained from\n                      <jats:italic>K<\/jats:italic>\n                      <jats:sub>DEEP<\/jats:sub>\n                      program were stated when compared to nelfinavir.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Here, we have demonstrated for the first time that ciprofloxacin and moxifloxacin may interact with COVID-19 Main Protease (M\n                      <jats:sup>pro<\/jats:sup>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43440-020-00169-0","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T15:03:21Z","timestamp":1602774201000},"page":"1553-1561","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis"],"prefix":"10.1007","volume":"72","author":[{"given":"Krzysztof","family":"Marciniec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2247-3004","authenticated-orcid":false,"given":"Artur","family":"Beberok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"P\u0119cak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanis\u0142aw","family":"Boryczka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Wrze\u015bniok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"169_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1099\/jmm.0.000475","volume":"66","author":"S Correia","year":"2017","unstructured":"Correia S, Poeta P, H\u00e9braud M, Capelo JL, Igrejas G. Mechanisms of quinolone action and resistance: where do we stand? J Med Microbiol. 2017;66:551\u20139.","journal-title":"J Med Microbiol"},{"key":"169_CR2","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1016\/j.bmc.2019.05.038","volume":"27","author":"GARY Suaifan","year":"2019","unstructured":"Suaifan GARY, Mohammed AAM. Fluoroquinolones structural and medicinal developments (2013\u20132018): where are we now? Bioorg Med Chem. 2019;27:3005\u201360.","journal-title":"Bioorg Med Chem"},{"key":"169_CR3","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00706-018-2215-x","volume":"149","author":"J Fedorowicz","year":"2018","unstructured":"Fedorowicz J, S\u0105czewski J. Modifications of quinolones and fluoroquinolones: hybrid compounds and dual-action molecules. Monatsh Chem. 2018;149:1199\u2013245.","journal-title":"Monatsh Chem"},{"key":"169_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2174\/1568005043340920","volume":"4","author":"S Richter","year":"2004","unstructured":"Richter S, Parolin C, Palumbo M, Pal\u00f9 G. Antiviral properties of quinolone-based drugs. Curr Drug Targets Infect Disord. 2004;4:111\u20136.","journal-title":"Curr Drug Targets Infect Disord"},{"key":"169_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3851\/IMP1937","volume":"17","author":"IA Khan","year":"2012","unstructured":"Khan IA, Siddiqui S, Rehmani S, Kazmi SU, Ali SH. Fluoroquinolones inhibit HCV by targeting its helicase. Antivir Ther. 2012;17:467\u201376.","journal-title":"Antivir Ther"},{"key":"169_CR6","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.bbmt.2010.12.700","volume":"17","author":"AN Miller","year":"2011","unstructured":"Miller AN, Glode A, Hogan KR, Schaub C, Kramer C, Stuart RK, et al. Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011;17:1176\u201381.","journal-title":"Biol Blood Marrow Transplant"},{"key":"169_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s10096-014-2296-3","volume":"34","author":"A Dalhoff","year":"2015","unstructured":"Dalhoff A. Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action? Eur J Clin Microbiol Infect Dis. 2015;34:661\u20138.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"169_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2020.06.004","author":"I Karampela","year":"2020","unstructured":"Karampela I, Dalamaga M. Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19? Arch Med Res. 2020. https:\/\/doi.org\/10.1016\/j.arcmed.2020.06.004.","journal-title":"Arch Med Res"},{"issue":"12","key":"169_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/v12020244","volume":"22","author":"J Xu","year":"2020","unstructured":"Xu J, Zhao S, Teng T, Abdalla AE, Zhu W, Xie L, et al. Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses. 2020;22(12):244.","journal-title":"Viruses"},{"key":"169_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jmii.2020.02.001","volume":"53","author":"PI Lee","year":"2020","unstructured":"Lee PI, Hsueh PR. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect. 2020;53:365\u20137.","journal-title":"J Microbiol Immunol Infect"},{"key":"169_CR11","doi-asserted-by":"publisher","first-page":"101578","DOI":"10.1016\/j.tmaid.2020.101578","volume":"33","author":"AJ Rodr\u00edguez-Morales","year":"2020","unstructured":"Rodr\u00edguez-Morales AJ, MacGregor K, Kanagarajah S, Patel D, Schlagenhauf P. Going global\u2014travel and the 2019 novel coronavirus. Travel Med Infect Dis. 2020;33:101578.","journal-title":"Travel Med Infect Dis"},{"key":"169_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jgg.2020.02.001","volume":"47","author":"X Liu","year":"2020","unstructured":"Liu X, Wang XJ. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J Genet Genom. 2020;47:119\u201321.","journal-title":"J Genet Genom"},{"key":"169_CR13","doi-asserted-by":"publisher","unstructured":"Fearon D,\u00a0Powell AJ,\u00a0Douangamath A,\u00a0Owen CD,\u00a0Wild C,\u00a0Krojer, T, et al. PanDDA analysis group deposition\u2014crystal structure of COVID-19 main protease in complex with Z1220452176. 2020. https:\/\/doi.org\/10.2210\/pdb5r7z\/pdb.","DOI":"10.2210\/pdb5r7z\/pdb"},{"key":"169_CR14","doi-asserted-by":"publisher","unstructured":"Liu X, Zhang B, Jin Z, Yang H, Rao Z. The crystal structure of COVID-19 main protease in complex with an inhibitor N3. 2020. https:\/\/doi.org\/10.2210\/pdb6LU7\/pdb.","DOI":"10.2210\/pdb6LU7\/pdb"},{"issue":"11","key":"169_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/v11020197","volume":"25","author":"KO Chang","year":"2019","unstructured":"Chang KO, Kim Y, Lovell S, Rathnayake AD, Groutas WC. Antiviral drug discovery: norovirus proteases and development of inhibitors. Viruses. 2019;25(11):197.","journal-title":"Viruses"},{"key":"169_CR16","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.07.981928","author":"W Rut","year":"2020","unstructured":"Rut W, Groborz K, Zhang L, Sun X, Zmudzinski M, Hilgenfeld R, et al. Substrate specificity profiling of SARS-CoV-2 Mpro protease provides basis for anti COVID-19 drug design. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.07.981928.","journal-title":"bioRxiv"},{"key":"169_CR17","volume-title":"Gaussian 16, revision A","author":"MJ Frisch","year":"2016","unstructured":"Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, et al. Gaussian 16, revision A. Wallingford: Gaussian Inc.; 2016."},{"key":"169_CR18","volume-title":"Virtual screening in drug discovery","author":"JC Cole","year":"2005","unstructured":"Cole JC, Nissink JWM, Taylor R. Protein-ligand docking and virtual screening with GOLD in virtual screening in drug discovery. In: Shoichet B, Alvarez J, editors. Virtual screening in drug discovery. Boca Raton: CRC Press; 2005."},{"key":"169_CR19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","volume":"267","author":"G Jones","year":"1997","unstructured":"Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997;267:727\u201348.","journal-title":"J Mol Biol"},{"key":"169_CR20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1021\/acs.jcim.7b00650","volume":"58","author":"J Jim\u00e9nez","year":"2018","unstructured":"Jim\u00e9nez J, \u0160kali\u010d M, Mart\u00ednez-Rosell G. Gianni De Fabritiis protein-ligand absolute binding affinity prediction via 3D-convolutional neural networks. J Chem Inf Model. 2018;58:287\u201396.","journal-title":"J Chem Inf Model"},{"key":"169_CR21","volume-title":"Discovery studio modeling environment; release 2017","author":"Dessault Systemes BIOVIA","year":"2016","unstructured":"Dessault Systemes BIOVIA. Discovery studio modeling environment; release 2017. San Diego: Dessault Systemes; 2016."},{"key":"169_CR22","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1002\/jcc.20289","volume":"26","author":"JC Phillips","year":"2005","unstructured":"Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, et al. Scalable molecular dynamics with NAMD. J Comput Chem. 2005;26:1781\u2013802.","journal-title":"J Comput Chem"},{"key":"169_CR23","doi-asserted-by":"publisher","first-page":"26536","DOI":"10.1038\/srep26536","volume":"6","author":"JV Ribeiro","year":"2016","unstructured":"Ribeiro JV, Bernardi RC, Rudack T, Stone JE, Phillips JC, Freddolino PL, et al. Integrative molecular dynamics toolkit for novices and experts. Sci Rep. 2016;6:26536.","journal-title":"Sci Rep"},{"key":"169_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey W, Dalke A, Schulten K. VMD\u2014visual molecular dynamics. J Mol Graph. 1996;14:33\u20138.","journal-title":"J Mol Graph"},{"key":"169_CR25","doi-asserted-by":"crossref","unstructured":"Khaerunnisa S, Kurniawan H, Awaluddin R, Suhartati S, Soetjipto S. Potential inhibitor of COVID-19 Main Protease (Mpro) from several medicinal plant compounds by molecular docking study. Preprints 2020, 2020030226.","DOI":"10.20944\/preprints202003.0226.v1"},{"key":"169_CR26","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2165\/00002018-200932050-00001","volume":"32","author":"F Van Bambeke","year":"2009","unstructured":"Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf. 2009;32:359\u201378.","journal-title":"Drug Saf"},{"key":"169_CR27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1086\/428055","volume":"41","author":"RC Owens Jr","year":"2005","unstructured":"Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41:144\u201357.","journal-title":"Clin Infect Dis"},{"key":"169_CR28","first-page":"455","volume":"65","author":"CM Oliphant","year":"2002","unstructured":"Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Phys. 2002;65:455\u201364.","journal-title":"Am Fam Phys"},{"key":"169_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000238860","volume":"37","author":"R Rohwedder","year":"1991","unstructured":"Rohwedder R, Bergan T, Caruso E, Thorsteinsson SB, Torre HD, et al. Penetration of ciprofloxacin and metabolites into human lung, bronchial and pleural tissue after 250 and 500 mg oral ciprofloxacin. Chemotherapy. 1991;37:229\u201338.","journal-title":"Chemotherapy"},{"key":"169_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1752-1947-4-111","volume":"4","author":"IS Kourbeti","year":"2010","unstructured":"Kourbeti IS, Alegakis DE, Maraki S, Samonis G. Impact of prolonged treatment with high-dose ciprofloxacin on human gut flora: a case report. J Med Case Rep. 2010;4:111.","journal-title":"J Med Case Rep"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00169-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-020-00169-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00169-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T21:05:32Z","timestamp":1634245532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-020-00169-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["169"],"URL":"https:\/\/doi.org\/10.1007\/s43440-020-00169-0","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"22 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"We declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}